Cancer Genetics Inc. (NASDAQ:CGIX)’s share price was up 9.4% on Friday . The stock traded as high as $2.10 and last traded at $2.10, with a volume of 101,922 shares trading hands. The stock had previously closed at $1.92.

Separately, Zacks Investment Research cut shares of Cancer Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, April 21st.

The company has a 50-day moving average of $2.04 and a 200-day moving average of $2.32. The stock’s market cap is $29.62 million.

Cancer Genetics (NASDAQ:CGIX) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.05. The firm earned $7 million during the quarter, compared to analysts’ expectations of $6.50 million. During the same quarter in the previous year, the firm posted ($0.51) EPS. Cancer Genetics’s revenue was up 67.3% compared to the same quarter last year. Equities analysts forecast that Cancer Genetics Inc. will post ($1.19) earnings per share for the current year.

Cancer Genetics, Inc is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.